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Abstract 
Aim: Given the conflicting evidence of sodium-glucose cotransporter 2 (SGLT2) 
inhibitors on bone health in patients with type 2 diabetes Mellitus (T2DM), we aimed to 
evaluate the comparative effects of SGLT2 inhibitors on risk of bone fracture.  
Methods: PubMed, EMBASE, CENTRAL, and ClinicalTrials.gov were systematically 
searched from inception to January 27, 2016 to identify RCTs reporting the outcome of 
fracture in T2DM patients with the use of SGLT2 inhibitors. A pairwise and network 
meta-analyses, as well as a cumulative meta-analysis were performed to calculate their 
odds ratios (ORs) and 95% confidence intervals (CIs).  
Results: A total of 38 eligible RCTs (10 canagliflozin, 15 dapagliflozin, and 13 
empagliflozin) involving 30,384 patients with periods of follow-up ranged from 24 to 160 
weeks were included. The fracture event rates were 1.59% in the SGLT2 inhibitor groups 
and 1.56% in the control groups. The incidence of fracture event was similar among 
these three SGLT2 inhibitor groups. Compared with placebo, canagliflozin (OR, 1.15; 
95%CI, 0.71 to 1.88), dapagliflozin (OR, 0.68; 95%CI, 0.37 to 1.25), and empagliflozin 
(OR, 0.93; 95%CI, 0.74 to 1.18) was not significantly associated with an increased risk of 
fracture. Our cumulative meta-analysis indicated the robustness of our null findings of 
SGLT2 inhibitors.  
Conclusions: Our meta-analysis based on available RCT data does not support the 
harm effect of SGLT2 inhibitors on fracture, although future safety monitoring from RCT 
and real-world data with detailed information on bone health is warranted.  
Keywords: SGLT2 inhibitor, Fracture, Type 2 diabetes, Meta-analysis 
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Introduction 
Patients with type 2 diabetes mellitus (T2DM) are at high risk for fracture, especially in 
the elderly patients [1, 2]. Though the precise mechanisms are unclear, several diabetic 
complications, such as hypoglycemic events, sensory neuropathy, nephropathy, and 
retinopathy, contribute to increased fracture risk [3]. Furthermore, some 
glucose-lowering agents may have potential to affect the risk of fracture [4]. 
Sodium glucose cotransporter 2 (SGLT2) inhibitors were recently approved for treating 
T2DM [5], which offer a novel insulin independent hypoglycemia mechanism by 
selectively inhibiting renal glucose reabsorption to increase urinary glucose excretion [6, 
7]. As a result, SGLT2 inhibitors cause osmotic diuresis effect that is related to volume 
depletion and maybe electrolytes imbalance. Possible changes of calcium and 
phosphate could adversely affect bone health [8].  
Recently, the increased number of reports of bone fractures in clinical trials of SGLT2 
inhibitors raised a safety concern [8]. One randomized trial in the elder patients with 
T2DM showed that canagliflozin slightly reduced the total hip bone mineral density (BMD) 
and increased the bone turnover markers over 104 weeks follow-up [9]. In September, 
2015, the U.S. Food and Drug Administration (FDA) strengthened the fracture warning 
for canagliflozin by adding a new Warning and Precaution and revising the Adverse 
Reactions section of the labels [10]. A pooled analysis of 10 randomized trials suggested 
that the increased risk of fractures associated with canagliflozin was indeed driven by a 
significantly high fracture rate in patients with elevated cardiovascular disease risk [11]. 
One trial reported that patients with moderate renal impairment received dapagliflozin  
and experienced more bone fracture events than placebo over 104 weeks of 
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follow-up[12]. In contrast, fewer fracture events of empagliflozin were reported as 
compared with placebo in patients with chronic kidney disease [13].  
Given conflicting results from individual RCTs, we therefore performed a comprehensive 
network meta-analysis to synthesize all available RCT data to evaluate the comparative 
effects of SGLT2 inhibitors on fracture risk in patients with T2DM. We also conducted a 
cumulative meta-analysis to assess the results robustness. 
 
Methods 
This review was performed according to the checklist of the PRISMA extension 
statement for reporting of systematic reviews incorporating network meta-analyses of 
health care interventions [14].  
Search strategy  
PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were 
comprehensively searched from inception to January 27, 2016 to identify eligible RCTs. 
We used the following relevant search terms: random, RCTs, sodium–glucose 
cotransporter, SGLT2, SGLT-2, and the names of individual SGLT2 inhibitors 
(empagliflozin, dapagliflozin, canagliflozin, sotagliflozin, luseogliflozin, ipragliflozin, 
remogliflozin etabonate, tofogliflozin, and ertugliflozin). No restrictions of language, year 
of publication, or publication status were applied. In addition, a manual search was 
carried out by searching the references of included trials and relevant meta-analyses, as 
well as ClinicalTrials.gov to identify other published and unpublished trials. Detailed 
information about the search strategy is presented on Table S1.  
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Study selection and data extraction 
We included RCTs that compared SGLT2 inhibitors with placebo or other active 
antidiabetic treatments in adult patients with T2DM. The follow-up periods required at 
least 24 weeks and fracture events were reported on published articles. In addition, the 
trials with results presented on ClinicalTrials.gov were also considered. Events of any 
type of fracture were considered the primary outcome and the change of BMD as the 
secondary outcome. The fracture event was reported by investigators as an adverse 
event (or serious adverse event) identified in the database using pre-specified lists from 
the Medical Dictionary for Regulatory Activities (MedDRA). Conference abstracts were 
excluded due to lack of detailed information assessing the trials’ characteristics, 
definition of outcome, and trial quality. 
Two reviewers independently did the study selection and data extraction, and any 
disagreements were resolved by consensus or referral to a third reviewer. A 
standardized data extraction form was developed to extract the following data: first 
author (publication year), study characteristics (country of origin, funding, and follow-up), 
characteristics of patients (inclusion criteria, background treatments, mean age, 
proportion of men, duration of T2DM, baseline glycated haemoglobin (HbA1c)%, body 
mass index (BMI), and pre-existing cardiovascular disease or chronic kidney disease, 
interventions (type and dose of SGLT2 inhibitors), and the outcomes (fracture events 
and BMD).  
If multiple reports from the same population were retrieved, only the most complete 
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and/or more recently reported data were used. If fracture events were not reported in the 
manuscript, the data from the “Serious Adverse Events” section on the ClinicalTrials.gov 
were extracted. In addition, if fracture outcomes were not reported on ClinicalTrials.gov, 
the incidence of the events was assumed to be zero. If two different comparison groups 
of non-overlapping patients (ie, A vs B and C vs D) were included in the same report, 
each comparison was considered separately. If three arms (ie, A vs B vs A+B) were 
evaluated in the RCTs, only two arms (A vs B) were included. When placebo was 
switched to an active comparator in the extended period, only the period with the 
placebo was documented. If any data were unclear or missing, the authors of the original 
RCTs were contacted for further information.  
Quality assessment—risk of bias  
We used Cochrane risk of bias tool to assess the quality of RCTs on 5 domains [15]. Two 
authors independently reviewed and judged each RCT as low risk of bias, high risk of 
bias, or unclear risk of bias for each of the following items: random sequence generation 
(selection bias), allocation concealment (selection bias), blinding (performance bias and 
detection bias), incomplete outcome data (attrition bias), and selective reporting 
(reporting bias).  
Statistical analysis  
Two types of meta-analysis, pairwise and network meta-analysis were performed to 
calculate their odds ratios (ORs) and 95% confidence intervals (CIs). All meta-analysis 
was performed with STATA (Version 14; Stata Corp., College Station, TX). 
For pairwise meta-analysis, Peto’s method was undertook to calculate the ORs for direct 
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comparisons between therapeutic regimens due to low event rate [16]. An I² statistic was 
used to evaluate the presence of heterogeneity within meta-analyses, with I2 of 25, 50, 
and 75 indicating low, medium, and high heterogeneity, respectively [17]. The source of 
heterogeneity was further explored in the following pre-specified subgroups: 1) type of 
SGLT2 inhibitors (canagliflozin vs. dapagliflozin vs. empagliflozin); 2) type of control 
groups (placebo vs. active treatment); 3) length of trial duration (<52 vs. ≥52 weeks); 4) 
mode of therapy (monotherapy vs. combination therapy); 5) race/ethnicity ( White vs. 
Asian); 6) pre-existing cardiovascular disease (Yes vs. No); 7) pre-existing chronic 
kidney disease (Yes vs. No); 8) age (<60 years vs. ≥ 60 years); and 9) data source 
(publications vs. Clinical trial registration). In addition, a cumulative meta-analysis was 
performed to test the stability of our findings with the accumulation of data over time. 
Finally, potential publication bias was assessed by Begg’s or Egg’s tests, as well as a 
visual inspection of the funnel plots. 
For indirect and mixed comparisons, a network meta-analysis with a random-effects 
model was used to compare different interventions [18, 19]. The network meta-analysis 
was performed with STATA version 13.1 using the “mvmeta” command and programmed 
STATA routines [18, 19]. For zero-event RCT, a 0.5 zero-cell correction was applied 
before meta-analysis[20]. To rank the SGLT2 inhibitors for a specified outcome, we 
estimated the relative ranking probabilities of each treatment using surface under the 
cumulative ranking curve (SUCRA), and mean ranks. For incidence of fracture, large 
SUCRA probability and lower mean rank indicate a safer intervention[21]. The 
heterogeneity variance (tau) estimated by a restricted maximum likelihood method was 
employed to investigate between-study heterogeneity [22] . 
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To check for the presence of inconsistency, a loop inconsistency specific approach was 
introduced to evaluate the difference between direct and indirect estimates for a specific 
comparison [23]. To check the assumption of consistency in the entire network, a 
design-by-treatment interaction model by using the χ2 test was used [24]. In addition, a 
comparison-adjusted funnel plot was used to assess small study effects within a network 
of interventions [25]. 
Results 
Study characteristics 
A total of 1,268 citations were retrieved through electronic search, and then 172 
potentially eligible reports were identified by reviewing study titles and abstracts. One 
hundred and thirty-four reports were excluded for the following reasons: conference 
abstracts (n= 75), no reporting fracture outcomes (n= 23), duplications with the same 
data source (n= 19), or follow-up period of less than 24 weeks (n=17). The RCTs 
registered on ClinicalTrials.gov were additionally checked and two RCTs were included. 
Finally, 38 RCTs were eligible and included in this meta-analysis (Figure 1).  
The Table S2 summarized the study characteristics of the 38 trials totaling 30,384 
patients, who were randomly assigned to each of SGLT2 inhibitors (canagliflozin, 
dapagliflozin, and empagliflozin) or control groups (placebo or other active anti-diabetic 
treatments). Sample sizes of individual trials were between 180 and 7,020 participants 
and the periods of follow up ranged from 24 to 160 weeks. One trial provided two 
independent datasets for two different comparisons (empagliflozin vs. metformin and 
empagliflozin vs. sitagliptin), which we considered separately [26]. The data of two trials 
9	
	
were presented together on the ClinicalTrials.gov so we included the combined data as 
one independent trial [27, 28] . 
The risk of bias for the 38 RCTs was summarized as follows (Figure S1): 31 RCTs 
reported adequate random sequence generation; 28 RCTs reported adequate allocation 
concealment; masking conditions were high in 3 RCTs, of which 2 RCTs were open label 
in extended period and 1 RCT set one arm with open label; and 13 RCTs reported any 
fracture events. All of the trials were funded by industrial companies.  
Risk of any types of bone fracture 
Pairwise meta-analysis and cumulative meta-analysis 
The analyses of fracture events included data from 38 trials reporting 496 events among 
30,384 patients (a raw event rate of 1.63%). The event rates were 1.59% in the SGLT2 
inhibitor treatment groups and 1.56% in the control groups. The results of pairwise 
meta-analysis were presented in Figure 2. There was no significant difference in the risk 
of fracture between SGLT2 inhibitors and controls (OR, 1.02; 95%CI, 0.84 to 1.23), with 
low statistical heterogeneity (I2=22.8%). None of the subgroup analyses showed 
significant results. SGLT2 inhibitors appeared to increase the risk of facture in Asian 
population (OR, 2.05; 95%CI, 0.86 to 4.87), but there was not statistically significant. 
Furthermore, the cumulative meta-analysis by publication year showed that the result 
gradually became stable and toward the null (Figure 3). There was no evidence of 
substantial publication bias in our analysis, based on the Egger’s test (P = 0.61), Begg’s 
test (P = 0.43), and on visual inspection of the funnel plot (Figure S2). 
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Network meta-analysis 
Figure S3 and Figure 4 displayed the trial network and the results of network 
meta-analysis, respectively. Compared with placebo, Canagliflozin (OR, 1.15; 95%CI, 
0.71 to 1.88), dapagliflozin (OR, 0.68; 95%CI, 0.37 to 1.25), and empagliflozin (OR, 0.93; 
95%CI, 0.74 to 1.18) was not significantly associated with an increased risk of fracture.). 
The incidence of fracture was similar among these three SGLT2 inhibitors. There was a 
low level of statistical heterogeneity (tau≈0), no inconsistency between direct and indirect 
estimates (all 95%CIs across zero) and no global inconsistency within any network were 
detected (P=0.95). In addition, the comparison-adjusted funnel plot indicated absence of 
small-study effects (Figure S4). 
Changes in bone mineral density 
We identified 2 relevant RCTs that evaluated the effect of SGLT2 inhibitors on the 
changes in BMD [29, 30]. One RCT with 182 T2DM patients showed no significant 
differences between dapagliflozin and placebo in BMD expressed as adjusted mean 
percent change from baseline at week 102 in any of the three regions of lumbar spine, 
femoral neck and total hip [29]. However, the other RCT with 716 T2DM patients showed 
a small, statistically significant reduction in BMD at the total hip over 104 weeks follow- 
up with the use of canagliflozin [30] . 
 
Discussion 
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Our meta-analysis included 38 RCTs (30,384 patients) that reported fracture risk and 2 
RCTs with data on changes of BMD. The results from the direct and indirect evidence 
showed that SGLT2 inhibitors were not significantly associated with an increased risk of 
fracture. There was no evidence of any difference among these SGLT2 inhibitors. No 
significant difference was detected in the subgroup analyses. Our cumulative 
meta-analysis of RCTs ordered chronologically by publication year showed the 
robustness of our null findings.  
Recently, some potential mechanisms by which SGLT2 inhibitors might affect bone 
metabolism were brought forward [8]. Due to their mechanism of action and the excretion 
of sodium in urine, SGLT2 inhibitors may alter serum calcium and phosphate levels, and 
thereby affect bone mass and fracture risk [31]. Some studies show that SGLT2 
inhibitors are associated with small increases in serum inorganic phosphate and 
magnesium, but clinical relevance of these changes is unclear [32]. It is proposed that 
increased serum phosphate is likely to provoke secretion of parathyroid hormone (PTH), 
which enhances bone resorption and increase the risk of bone fractures [8]. Furthermore, 
serum PTH increases the concentrations of fibroblast growth factor 23 (FGF23), which 
has been associated with bone disease [33]. In addition, it is the fact that bone 
represents a substantial reservoir of sodium and that mobilization of bone sodium seems 
to require arginine vasopressin-dependent and independent mechanisms [34, 35]. 
Arginine vasopressin negatively regulates osteoblasts and stimulates osteoclasts [35]. 
Therefore, the hyponatremia caused by SGLT2 inhibitors might increase the 
osteoporosis and fracture risk. Previous studies showed that canagliflozin might increase 
bone turnover, with increases in serum of biomarkers for both bone resorption (collagen 
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type-1 beta-carboxytelopeptide) and bone formation (osteocalcin) [32], while 
dapagliflozin had no meaningful effect on makers of bone turnover [29]. Additionally, a 
decrease in BMD at total hip was detected in T2DM patients with the use of canagliflozin 
[30, 32], while dapagliflozin appeared to have no effect on BMD [29]. However, these 
limited data are preliminary and whether SGLT2 inhibitors have an effect on bone health 
biomarkers needed to be explored. 
Consistently, our findings and the results from one previous meta-analysis [36] do not 
support the adversely effect of SGLT2 inhibitors on fracture. Our meta-analysis included 
38 RCTs with 496 events among 30,384 T2DM patients. Moreover, our cumulative 
meta-analysis showed that the overall evidence was sufficient and the null results were 
robust. In addition, there was no evidence that individual SGLT2 inhibitor (e.g., 
canagliflozin, dapagliflozin, or empagliflozin) increased the fracture rate or had different 
effects. One pooled analysis of data from more than 11,000 patients with T2DM reported 
that empagliflozin was not associated with an increased risk of bone fractures versus 
placebo [37].	However, another pooled analysis of 10 trials showed that fracture risk was 
increased with canagliflozin treatment only in the patients who were older, with a prior 
history/risk of cardiovascular disease, and with lower baseline estimated glomerular 
filtration rate and higher baseline diuretic use [11]. Also, the author indicated that the 
increased fracture rate of canagliflozin may be due to chance or possibly other risk 
factors [11]. We performed multiple subgroup analyses to identify any clinically relevant 
subgroup effects based on patients’ characteristics (e.g., age, pre-existing 
cardiovascular disease, or chronic kidney disease). None of the subgroup analyses 
showed a significant difference in fracture risk. Intriguingly, our findings showed that 
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SGLT2 inhibitors had a tendency to increase the risk of fracture in Asian population. 
However, power was low because only 2,819 Asian patients with 24 events were 
included. Nevertheless, it is still difficult to draw the conclusion about long-term modest 
effect on fracture risk due to relatively short follow-up periods of included RCTs, which 
ranged from 24 to 160 weeks. Further studies with longer term follow-up are warranted 
to resolve uncertainty about the risk of fracture by SGLT2 inhibitors. 
Be different from the previous pairwise meta-analysis which was conducted with bone 
fracture event as a secondary outcome [36], our network meta-analysis considered the 
fracture events as primary outcomes of interest. This meta-analysis included the data up 
to Sept 30, 2015 and just only separately pooled the data from regulatory submissions 
(462 events; 29503 patients; RR, 0.99, 95% CI: 0.85 to 1.34) and scientific reports (396 
events; 13383 patients; RR, 0.96, 95% CI: 0.78 to 1.18) [36]. Conversely, our network 
meta-analysis with more restrict inclusion criteria provided more information and 
powerful evidence. First, we included more recent RCT data (38 RCTs with 496 events 
among 30,384 patients) from publications and clinical trial registration (up to Jan 27, 
2016). Second, we have relatively large number of eligible RCTs to perform subgroup 
analyses to explore the impact by trial or patients’ characteristics. Third, network 
meta-analysis was introduced to synthesize both direct and indirect evidence by 
maximizing available RCT data and explore the difference among these SGLT2 
inhibitors. Fourth, we also used a cumulative meta-analysis to test the evidence 
sufficiency and finding robustness. Finally, more bone health outcomes (e.g., BMD) were 
assessed in our meta-analysis.  
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However, several limitations of our study merit consideration. First, some trials are less 
likely to report the events of fracture in the articles published on peer reviewed journals, 
though additional data on ClinicalTrials.gov were searched to minimize publication bias 
and the outcome reporting bias. Due to none of the trials considered fractures as 
pre-specified adverse event endpoints, it did not allow a clear report the incidence of any 
fracture (e.g., osteoporotic fracture) and other bone health parameters (e.g., BMD). 
Second, some trials were unable to ascertain fracture cases due to short follow-up 
periods (up to about 160 weeks). Third, background treatments and patient 
characteristics varied among the RCTs and might contribute to heterogeneity, although 
low statistical heterogeneity and absence of inconsistency of our network model were 
detected. Finally, risk of fracture for other novel SGLT2 inhibitors remains uncertain due 
to lack of RCT data. 
In conclusions, current evidence suggested that SGLT2 inhibitors were not significantly 
associated with an increased risk of fracture in patients with T2DM. Since lack of detailed 
information on bone health outcome were reported and majority of RCTs were small and 
short term, future long term RCT and real-world data is warranted to draw more definitive 
conclusions regarding the bone effect of SGLT2 inhibitors. 
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Figure Legend: 
 
Figure 1. Flow chart of the identification of eligible trials. 
 
Figure 2. Overall and subgroup pairwise meta-analysis of SGLT2 inhibitor on risk 
of fracture.  
Figure 3. Cumulative meta-analysis of SGLT2 inhibitor on risk of fracture.  
A null effect was stable after 24 RCTs and remained unchanged after additional inclusion 
of subsequent RCTs by publication years 
Figure 4. Network meta-analysis of SGLT2 inhibitor on risk of fracture.  
Common heterogeneity variables (tau) in the network meta-analysis were low (tau≈0). 
CANA, Canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; PLA, placebo; ACT, 
active treatments; CI, confidence interval.  
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